Literature DB >> 2787797

Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells.

K Oomori, Y Kikuchi, M Miyauchi, T Kita, I Iwano, I Kizawa, J Hirata, E Kuki.   

Abstract

The effect of intraperitoneal instillations of interleukin-2 (IL-2) and/or lymphokine-activated killer (LAK) cells on the ascites formation and the survival time was examined using nude mice as a model, with malignant ascites produced by intraperitoneal inoculation of human ovarian cancer cells derived from ascites of a patient with serous cystadenocarcinoma of the ovary. Twenty-eight days after tumor inoculation, all nude mice in the untreated group and in the group treated with spleen cells alone formed ascites. Two of ten nude mice treated with IL-2 alone after tumor inoculation survived without forming ascites during the experimental period. On the other hand, all nude mice treated with LAK cells alone had formed ascites 14 days after tumor inoculation. When LAK cells and IL-2 were combined, five of ten mice survived without forming ascites during the experimental period. The survival time of the group treated with IL-2 alone was significantly prolonged compared to the groups that received medium alone, spleen cells alone and LAK cells alone. When administration of LAK cells was followed by IL-2, the survival time was further prolonged.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787797     DOI: 10.1007/bf00391692

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  13 in total

Review 1.  Biologic therapy for the treatment of malignant common epithelial tumors of the ovary.

Authors:  T C Hamilton; R F Ozols; D L Longo
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

2.  Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.

Authors:  Y Kikuchi; I Kizawa; K Oomori; M Miyauchi; T Kita; M Sugita; Y Tenjin; K Kato
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

3.  Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2.

Authors:  M A Palladino; K Welte; A M Carroll; H F Oettgen
Journal:  Cell Immunol       Date:  1984-07       Impact factor: 4.868

4.  Enhancement of antineoplastic effects of cisplatin by calmodulin antagonists in nude mice bearing human ovarian carcinoma.

Authors:  Y Kikuchi; K Oomori; I Kizawa; J Hirata; T Kita; M Miyauchi; K Kato
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

5.  Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

6.  Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo.

Authors:  M A Cheever; P D Greenberg; C Irle; J A Thompson; D L Urdal; D Y Mochizuki; C S Henney; S Gillis
Journal:  J Immunol       Date:  1984-05       Impact factor: 5.422

7.  Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

Authors:  W H West; K W Tauer; J R Yannelli; G D Marshall; D W Orr; G B Thurman; R K Oldham
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

9.  The inhibitory effect of tranexamic acid on human ovarian carcinoma cell grown in vitro and in vivo.

Authors:  Y Kikuchi; I Kizawa; K Oomori; E Kuki; K Kato
Journal:  Gynecol Oncol       Date:  1986-06       Impact factor: 5.482

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  1 in total

1.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.